Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset to Ipsen's Rare Disease pipeline

24-Jul-2026

Ipsen announced it has completed the acquisition of Memo Therapeutics AG, a late-stage biotech company focused on potravitug, an anti-BK polyomavirus monoclonal antibody.

AI-generated image

Symbolic image

Potravitug is a first-in-class monoclonal antibody targeting BK polyomavirus (BKPyV) reactivation in kidney transplant recipients. It has shown promising results in clinical trials, demonstrating a significant anti-viral response and resolution of BKPyV associated nephropathy. These findings are based on the Phase II SAFE KIDNEY II trial, the largest placebo-controlled study conducted in this patient population, with additional analyses presented at leading international renal and transplant congresses further supporting its clinical profile and the next stages of clinical development.

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...